Which ASX Healthcare Stocks Have Delivered Triple-Digit Returns Over the Past Year?

Sonal Goyal

03 July 2026 05:01 PM AEST

Which ASX Healthcare Stocks Have Delivered Triple-Digit Returns Over the Past Year?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• Lumos Diagnostics, HeraMED and Intelicare have posted notable one-year gains.

• Digital healthcare, diagnostics and smart care technologies continue attracting investor attention.

• Commercial execution and customer adoption remain key areas of focus for investors.

Australia's healthcare sector has produced several notable performers over the past year as investors increasingly focused on companies developing digital healthcare, diagnostics and connected care technologies. While individual share price movements varied during Thursday's trading session, several healthcare companies have continued to attract market attention following significant gains over the past twelve months.

Among them, Lumos Diagnostics Holdings Ltd (ASX:LDX), HeraMED Ltd (ASX:HMD) and Intelicare Holdings Ltd (ASX:ICR) have delivered substantial one-year returns while continuing to pursue commercial expansion across different areas of healthcare technology.

Lumos Diagnostics Expands Its Presence in Point-of-Care Testing

Lumos Diagnostics Holdings Ltd (ASX:LDX) has delivered an approximately 267% gain over the past year, while its shares added 4.76% during Thursday's trading session.

The company develops and commercialises point-of-care diagnostic technologies, including FebriDx®, a rapid diagnostic test designed to help differentiate bacterial and viral respiratory infections. Lumos also operates a contract development and manufacturing (CDMO) business serving healthcare and diagnostics companies.

Investors continue monitoring product adoption, commercial partnerships, regulatory milestones and international expansion as the company seeks to broaden its diagnostics business.

HeraMED Focuses on Digital Maternal Healthcare

HeraMED Ltd (ASX:HMD) has recorded an approximately 320% gain over the past year, making it one of the stronger performers within the ASX healthcare sector. The stock was unchanged during Thursday's session but remains firmly on investors' watchlists.

The company develops the HeraCARE® digital maternal healthcare platform, which combines connected medical devices and software to support remote pregnancy monitoring. Growing adoption of digital healthcare technologies has continued to increase interest in companies offering remote patient monitoring solutions.

Market participants continue watching healthcare provider adoption, commercial agreements and international expansion opportunities as HeraMED advances its business strategy.

Intelicare Benefits from Growing Demand for Smart Care Solutions

Intelicare Holdings Ltd (ASX:ICR) has delivered an approximately 120% return over the past year, while its shares gained 4.76% during today's session.

The company develops AI-enabled remote monitoring solutions for aged care, disability care and independent living. Its sensor-based platform uses artificial intelligence and predictive analytics to help care providers monitor wellbeing and identify behavioural changes without relying on wearable devices.

As ageing populations continue driving demand for digital healthcare solutions, investors remain focused on customer acquisition, commercial deployments and recurring software revenue growth.

Healthcare Technology Continues to Draw Investor Interest

The three companies operate across different healthcare segments but share exposure to structural growth trends transforming healthcare delivery.

Rapid diagnostics continue supporting faster clinical decision-making, digital maternal healthcare is expanding alongside remote patient monitoring, while AI-powered aged care technologies are becoming increasingly important as healthcare providers adopt smarter care solutions.

Although each business has followed a different growth path, commercial execution, customer adoption and regulatory progress remain important considerations for investors evaluating future opportunities.

What Investors Could Watch Next

Investors are expected to monitor several common themes across these healthcare companies, including:

• Commercial partnerships and customer adoption

• Expansion into domestic and international healthcare markets

• Regulatory approvals and product development milestones

• Growth in recurring revenue and commercial contracts

• Broader adoption of digital healthcare technologies

Developments across these areas may continue influencing market sentiment toward the sector.

Conclusion

Lumos Diagnostics (ASX:LDX), HeraMED (ASX:HMD) and Intelicare Holdings (ASX:ICR) have each delivered notable one-year returns while operating in different segments of the healthcare technology market. Their businesses span point-of-care diagnostics, digital maternal healthcare and AI-powered aged care solutions, reflecting the diversity of innovation emerging across the ASX healthcare sector.

As these companies continue advancing their commercial strategies, investors are expected to monitor customer adoption, partnership activity and regulatory developments that could influence their future growth trajectories.

FAQs

Q: Which ASX healthcare stocks featured strong one-year returns?

A: Lumos Diagnostics (ASX:LDX), HeraMED (ASX:HMD) and Intelicare Holdings (ASX:ICR) have each delivered notable gains over the past year.

Q: What does Lumos Diagnostics do?

A: Lumos develops rapid point-of-care diagnostic tests, including FebriDx®, and also provides contract development and manufacturing services.

Q: What is HeraMED known for?

A: HeraMED develops the HeraCARE® platform, a digital maternal healthcare solution for remote pregnancy monitoring.

Q: What does Intelicare Holdings do?

A: Intelicare provides AI-powered remote monitoring solutions for aged care, disability care and independent living using smart sensor technology.

Q: What could influence these healthcare stocks going forward?

A: Investors are likely to monitor commercial partnerships, customer adoption, regulatory milestones, international expansion and recurring revenue growth across each company.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.